Curis Lifesciences Pays Fine Over Delayed RPT Disclosure Compliance
Curis Lifesciences Limited has confirmed that it has paid a fine levied by the National Stock Exchange of India (NSE) concerning a delay in submitting its Related Party Transactions (RPT) disclosure for the half-year ended March 31, 2026. The company stated that the issue was due to unforeseen technical errors encountered during the electronic filing process.The Board of Directors reviewed the matter regarding the delayed submission of the RPT disclosure. While the internal report was prepared and ready for timely submission, the company faced technical errors on the NEAPS portal, which prevented successful transmission of the required documents.
The management clarified that this lapse in compliance arose solely from technical glitches and does not reflect the company's underlying governance standards. Curis Lifesciences Limited reaffirmed its ongoing commitment to maintaining the highest standards of corporate governance and compliance.
The fine, along with applicable Goods and Services Tax (GST), has been paid by the company. The details of the penalty are as follows:
| Parameter | Amount |
|---|---|
| Fine amount levied by NSE | ₹5,000 |
| GST @18% | ₹900 |
| Total fine payable | ₹5,900 |
The Board noted that the delayed compliance related to Regulation 23(9) of the SEBI (LODR) Regulations, 2015. The company ensured that all necessary financial penalties were cleared following the review of the non-compliance notice from the Exchange.
CURIS Stock Price Movement
Today, shares of Curis Lifesciences Limited edged higher, closing out the session at ₹100.95 after gaining 0.25%. The stock traded within a tight range for the day, having moved between a low of ₹98 and its final high of ₹100.95.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.